Long-term blood thinning in severe hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at using long-term blood thinners (anticoagulants) in adults with severe hemophilia A, a bleeding disorder. It aims to understand if this treatment can be safe and effective for patients who may need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with severe hemophilia A
- You have not said no to having your medical data used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how two different hemophilia A treatments affect bone health over time. It tests if one medicine is better at keeping bones strong than the other.
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study checks how people with severe hemophilia A are doing over time after joining a previous BioMarin study of BMN 270. It helps researchers understand long-term safety and outcomes and may support your ongoing care plan.
This Phase 1/2 study tests a one-time gene therapy (ASC618) to help the body make clotting factor for people with hemophilia A. It may reduce bleeding and the need for factor infusions, but you must meet several safety and eligibility checks.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.